This Biotech Is Up 300 In Two Months

LAS VEGAS, NV / ACCESSWIRE / April 20, 2016 / Sean Parker just made an incredible donation, and thus created the “Parker Institute for Cancer Immunotherapy.”

If you’re looking to follow his money into biotechs that are working toward immuno-oncology and peripheral solutions, I think you should strongly consider Propanc Health Group (PPCH).

SeeThruEquity just reiterated their 12 month price target of $0.87 cents per share for Propanc Health Group (PPCH). If it reaches this market that would represent a 2,800% gain!

The billionaire Silicon Valley veteran Sean Parker will inject $250 million into the immuno-oncology research field in an effort to boost cancer survival rates. He is donating the money to 6 cancer centers nationwide, including Houston’s University of Texas MD Anderson and New York’s Memorial Sloan Kettering. These centers will form the “Parker Institute for Cancer Immunotherapy” and will include over 40 laboratories and more than 300 researchers from across the 6 sites. This builds on the $600 million Parker put up to launch the Parker Foundation last year, with a particular focus on life sciences and also comes after he told FierceBiotech last year that he was moving into something big for immuno-oncology.

This comes three months after President Obama called for a $1 billion federal cancer research program that he dubbed a “Moonshot”, as the government hopes to foster collaboration between typically competing hospitals.

Parker is no dummy, the guy was in early on the MP3 craze, and Facebook. Smart people follow his money.

The CEO of SeeThruEquity made the following statement about Propanc Health Group (PPCH):

“As we have noted in our prior notes on the company, Propanc is pursuing a large market opportunity as it seeks to fast track the development of proenzyme related oncology products. The company first plans to develop clinical trials targeting pancreatic cancer and ovarian cancer, followed by colorectal cancer. The company will be targeting patients with limited therapeutic options for solid tumors, and in the future intends to develop products to treat early stage cancer, precancerous diseases and potentially as preventative treatment for patients at high risk of developing cancer based on genetic screening. According to Global Analyst Reports, the combined world market for pancreatic, ovarian and colorectal cancers are expected to reach over $12 billion by 2020,” commented Ajay Tandon, CEO of SeeThruEquity. “We are maintaining our 12-month price target of $0.87 per share.”

SeeThruEquity also highlighted several potential milestones coming up for the company. Milestones mean big news releases, big news releases bring new investors and new investors mean raised valuation.

Here are some of the milestones:

– Scheduled a scientific advice meeting with the MHRA (Medicines and Healthcare Products Regulatory Agency), UK, which is expected to occur during April. The meeting will include data from its recent 14-day dose range finding study in rats, which will be used to determine appropriate dosing levels for Propanc’s upcoming 28 day toxicology study.

– Propanc also expects to file an application for an orphan drug designation in the US and EU for pancreatic and ovarian cancers by the end of 2016. If accepted the designation could allow for an accelerated and less costly time clinical pathway for PRP.

– Propanc is targeting the commencement of early stage patient trials by the end of 2016/ early 2017.

A few other biotechs worth a look include:

Cara Therapeutics, Inc. (CARA), Celldex Therapeutics, Inc. (CLDX), Spectrum Pharmaceuticals, Inc. (SPPI), & PTC Therapeutics, Inc. (PTCT) are all drawing interest from investors.

But to reiterate, if PPCH can reach its $0.87 cent price target that would represent a 2,800% increase from these levels.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, Microcapspeculators.com may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns Microcapspeculators.com
may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC. has been compensated $67,000 by Propanc Health Group, Corp. for this news article and for previous as well as future news articles.

Contact:

Acrlasvegas@gmail.com

SOURCE: ACR Communication, LLC

ReleaseID: 439034